Skip to content
TirzepatideReport

Tirzepatide monograph · Evidence review

Aspen Tirzepatide Review: Cost, a Named Pharmacy & Honest Verdict (2026)

An honest 2026 review of Aspen tirzepatide — a named, accredited pharmacy, flat dose pricing, and a 3-month minimum commitment.

Researched & written by Alan Pierce · last updated

Clinical Pharmacology Writer

On this page

Editorial pick

CoreAge Rx

$149/mo flat

Doctor-reviewed tirzepatide with one flat price and built-in human support.

Advertising disclosure · we may earn a commission at no extra cost to you.

Check availability
vs median
$120/mo below the $269 median
Market
$109–$429/mo across 396 providers
Dispensed
Compounded tirzepatide (503A)

Popular alternative

yourEra

Transparent compounded tirzepatide with both molecules and a broad longevity menu, shipped nationwide — priced in the mid-market.

From $159/mo

Check yourEra availability

Aspen (Aspen Health Systems LLC) is a LegitScript-certified telehealth clinic, offering compounded semaglutide and tirzepatide as physician-chosen weekly injections with flat pricing at every dose. This review's own live check found the site's content is fully client-rendered — the figures below rest on prior research. Every fact here comes from the company's own published program.

What Aspen is

Aspen is registered as Aspen Health Systems LLC, at a Sheridan, WY address, serving all 50 states. This review's live attempt to independently verify the site found it renders almost entirely client-side — no pricing or pharmacy detail was present in the fetched content, so the figures below reflect prior research, not our own check.

§ Aspen — "Monthly" Plan, 3-Month Minimum

ItemDetail
PharmacyRed Rock Compounding Pharmacy, named
Tirzepatide$399/mo standing, $299/mo on 12-mo prepay
Real minimum commitment3 months, even on the "monthly" plan
Even the standard plan bills three months of medication upfront — read 'monthly' as the billing unit, not the commitment length.

A named, accredited pharmacy — a real positive,

Aspen names its dispensing pharmacy directly: Red Rock Compounding Pharmacy, described as LegitScript-certified and NABP-accredited, licensed in 49 states plus DC. Aspen's own LegitScript seal is reported with a specific, independently verifiable certificate number, #50306023. This review's own live pass could not reconfirm either detail against the rendered page, but naming a specific, accredited pharmacy rather than a vague "US-licensed pharmacy" is a genuinely stronger disclosure than most competitors offer, if accurate.

What Aspen costs — and the 3-month catch

Pricing is flat at every dose ("same price at every dose, no surprises"), with tirzepatide as low as $299/month on a 12-month prepay, or $399/month standing. The real catch: even the "monthly" plan requires a 3-month commitment, with three months of medication shipped and billed upfront — meaningfully less flexibility than a genuine month-to-month plan. A money-back guarantee is offered for patients who complete a full 28-week program without losing weight.

The brand-vs-compounded question

Aspen dispenses compounded semaglutide and tirzepatide only — no brand-name Wegovy, Zepbound, or Ozempic option. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

Aspen's real strengths is a named, accredited pharmacy (Red Rock Compounding Pharmacy) and a specific, verifiable LegitScript certificate number; flat pricing at every dose; free expedited shipping; zero-interest, no-credit-check prepay options; and a money-back guarantee for a completed 28-week program. The trade-offs: even the "monthly" plan requires a 3-month upfront commitment; standing month-to-month pricing is steep ($279-$399), with the lowest rates requiring longer prepay; the provider chooses your molecule rather than letting you freely pick; and it's an asynchronous model with no routine video visit. As with any GLP-1 program, read the commitment terms carefully before assuming "monthly" means no lock-in; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-11, and better than semaglutide head-to-head2 — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

Aspen's named, accredited pharmacy and specific LegitScript certificate number are genuine positives — but even its "monthly" plan requires a 3-month upfront commitment, and the provider chooses your molecule rather than you. If you want genuine month-to-month flexibility, compare it against Strut Health or ShedRx; if a named clinical team with brand-name access matters more, weigh Aspire Health. See our best tirzepatide providers ranking for the full field.

Frequently asked questions

How much does tirzepatide cost through Aspen?

$399/month standing, or as low as $299/month on a 12-month prepay. Pricing is flat at every dose.

Is Aspen's plan really month-to-month?

Not fully — even the 'monthly' plan requires a 3-month upfront commitment, with three months of medication shipped and billed at once.

Does Aspen name its compounding pharmacy?

Yes — Red Rock Compounding Pharmacy, described as LegitScript-certified and NABP-accredited, licensed in 49 states plus DC.

References(2)

  1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, and the SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
  2. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Bays HE, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).. New England Journal of Medicine. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/

About the author

Alan Pierce

Clinical Pharmacology Writer

About Tirzepatide Report · How we verify prices · This page last updated August 2026

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Related monograph sections

View all sections